Comparison of the clinical features and outcomes in two age-groups of elderly patients with atrial fibrillation

Clinical Interventions in Aging

Volumn 9, Issue , 2014, Pages 1335-1342

  Shao, Xing Hui ^a   Yang, Yan Min ^a   Zhu, Jun ^a   Zhang, Han ^a   Liu, Yao ^a   Gao, Xin ^a   Yu, Li Tian ^a   Liu, Li Sheng ^a   Zhao, Li ^b   Yu, Peng Fei ^c   Zhang, Hua ^d   He, Qing ^e   Gu, Xiao Dan ^f  

^a FUWAI HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c Ping Du People's Hospital   (China)

^d QINGDAO MUNICIPAL HOSPITAL   (China)

^e SICHUAN UNIVERSITY   (China)

^f Sixth Hospital of Chengdu   (China)

Author keywords

Atrial fibrillation; Geriatric patients; Major adverse cardiac events (MACE); Mortality

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; WARFARIN;

AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COGNITIVE DEFECT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; GERIATRIC PATIENT; HEART ATRIUM FIBRILLATION; HEART DISEASE; HUMAN; HYPERTENSION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; SLEEP DISORDERED BREATHING; VALVULAR HEART DISEASE; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; CHINA; CLINICAL TRIAL; COMPARATIVE STUDY; GERIATRIC ASSESSMENT; MULTICENTER STUDY; PREDICTIVE VALUE; PROSPECTIVE STUDY; REGISTER; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; CHINA; FEMALE; GERIATRIC ASSESSMENT; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS;

EID: 84907325303     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S67123     Document Type: Article

References (23)

1. Lip GY, Tse HF, Lane DA. Atrial fibrillation. Lancet. 2012;379(9816): 648-661.
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA: the journal of the American Medical Association. 2001;285(18):2370-2375.
3. Kazemian P, Oudit G, Jugdutt BI. Atrial fibrillation and heart failure in the elderly. Heart Fail Rev. 2012;17(4-5):597-613.
4. Lip GY. Using the CHA(2)DS(2)-VASc score for stroke risk stratification in atrial fibrillation: a clinical perspective. Exp Rev Cardiovasc Ther. 2013;11(3):259-262.
5. Kirchhof P, Lip GY, Van Gelder IC, et al. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference. Thromb Haemost. 2011;106(6):1012-1019.
6. Hylek EM, D'Antonio J, Evans-Molina C, Shea C, Henault LE, Regan S. Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke. 2006;37(4):1075-1080.
7. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370(9586):493-503.
8. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006; 114(2):119-125.
9. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369-2429.
10. Lip GY, Lim HS. Atrial fibrillation and stroke prevention. Lancet Neurol. 2007;6(11):981-993.
11. Van Staa TP, Setakis E, Di Tanna GL, Lane DA, Lip GY. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Haemost. 2011;9(1):39-48.
12. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182,678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500-1510.
13. Camm AJ, Lip GY, De Caterina R, et al. 2012 Focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719-2747.
14. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991;22(3):312-318.
15. Gallagher AM, Rietbrock S, Plumb J, van Staa TP. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost. 2008;6(9):1500-1506.
16. Nantsupawat T, Nugent K, Phrommintikul A. Atrial fibrillation in the elderly. Drugs Aging. 2013;30(8):593-601.
17. Guo Y, Wu Q, Zhang L, et al. Antithrombotic therapy in very elderly patients with atrial fibrillation: is it enough to assess thromboembolic risk? Clin Interv Aging. 2010;5:157-162.
18. Quilliam BJ, Lapane KL. Clinical correlates and drug treatment of residents with stroke in long-term care. Stroke. 2001;32(6):1385-1393.
19. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992.
20. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891.
21. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011; 123(21):2363-2372.
22. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax. 2008;63(9):831-838.
23. Lopez CM, House-Fancher MA. Management of atrial fibrillation in patients with chronic obstructive pulmonary disease. J Cardiovasc Nurs. 2005;20(2):133-140.